← back to search

Antje Beling

Humboldt-Universität zu Berlin · DE
Area of research
Cardiology and Cardiovascular Medicine · Immunology
Research interest
Research interests include Viral Infections and Immunology Research, interferon and immune responses, RNA regulation and disease, and Virus-based gene therapy research.
h-index
16
citations
959
works
39
NIH funding
primary concept
email

Recent publications

Assessing customized multivalent chemokine-binding peptide treatment in a murine model of coxsackievirus B3 myocarditis
Basic Research in Cardiology 2025cited by 3position: lastdoi
Decoding IFN-mediated immunity and cell dynamics in viral encephalitis: Insights from coxsackievirus B3 infection
iScience 2025cited by 2position: middledoi
ISG15 blocks cardiac glycolysis and ensures sufficient mitochondrial energy production during Coxsackievirus B3 infection
Cardiovascular Research 2024cited by 24position: lastdoi
Combination of FOLFOXIRI Drugs with Oncolytic Coxsackie B3 Virus PD-H Synergistically Induces Oncolysis in the Refractory Colorectal Cancer Cell Line Colo320
International Journal of Molecular Sciences 2024cited by 9position: middledoi
TF-FVIIa PAR2-β-Arrestin Signaling Sustains Organ Dysfunction in Coxsackievirus B3 Infection of Mice
Arteriosclerosis Thrombosis and Vascular Biology 2024cited by 3position: lastdoi
tRNA-like Transcripts from the NEAT1-MALAT1 Genomic Region Critically Influence Human Innate Immunity and Macrophage Functions
Cells 2022cited by 20position: middledoi
Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection
Nature Immunology 2021cited by 146position: middledoi
Ring finger protein 213 assembles into a sensor for ISGylated proteins with antimicrobial activity
Nature Communications 2021cited by 129position: middledoi
miR-375- and miR-1-Regulated Coxsackievirus B3 Has No Pancreas and Heart Toxicity But Strong Antitumor Efficiency in Colorectal Carcinomas
Human Gene Therapy 2021cited by 26position: middledoi
Mitigated viral myocarditis in A/J mice by the immunoproteasome inhibitor ONX 0914 depends on inhibition of systemic inflammatory responses in CoxsackievirusB3 infection
Basic Research in Cardiology 2021cited by 14position: lastdoi
Coxsackievirus B3 Exploits the Ubiquitin-Proteasome System to Facilitate Viral Replication
Viruses 2021cited by 8position: lastdoi
Coxsackievirus B3 Infection of Human iPSC Lines and Derived Primary Germ-Layer Cells Regarding Receptor Expression
International Journal of Molecular Sciences 2021cited by 5position: middledoi
Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation
Circulation 2020cited by 87position: lastdoi
Protein modification with ISG15 blocks coxsackievirus pathology by antiviral and metabolic reprogramming
Science Advances 2020cited by 52position: lastdoi
ONX 0914 Lacks Selectivity for the Cardiac Immunoproteasome in CoxsackievirusB3 Myocarditis of NMRI Mice and Promotes Virus-Mediated Tissue Damage
Cells 2020cited by 11position: lastdoi
Single-Point Mutations within the Coxsackie B Virus Receptor-Binding Site Promote Resistance against Soluble Virus Receptor Traps
Journal of Virology 2020cited by 6position: lastdoi
The in vivo ISGylome links ISG15 to metabolic pathways and autophagy upon Listeria monocytogenes infection
Nature Communications 2019cited by 101position: middledoi
Early Treatment of Coxsackievirus B3–Infected Animals With Soluble Coxsackievirus-Adenovirus Receptor Inhibits Development of Chronic Coxsackievirus B3 Cardiomyopathy
Circulation Heart Failure 2019cited by 24position: middledoi
Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas
Cardiovascular Research 2019cited by 23position: middledoi
The immunoproteasome‐specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis
EMBO Molecular Medicine 2018cited by 62position: lastdoi
Cysteine-Reactive Free ISG15 Generates IL-1β–Producing CD8α+ Dendritic Cells at the Site of Infection
The Journal of Immunology 2018cited by 42position: middledoi
Silencing the CSF-1 Axis Using Nanoparticle Encapsulated siRNA Mitigates Viral and Autoimmune Myocarditis
Frontiers in Immunology 2018cited by 34position: middledoi
Proteasomal Protein Degradation: Adaptation of Cellular Proteolysis With Impact on Virus—and Cytokine-Mediated Damage of Heart Tissue During Myocarditis
Frontiers in Immunology 2018cited by 14position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Karin Klingel · Saint Joseph Hospital12 papers (2018–2025)Meike Kespohl · Humboldt-Universität zu Berlin10 papers (2018–2025)Sandra Pinkert · Humboldt-Universität zu Berlin8 papers (2018–2025)Henry Fechner · Charité - Universitätsmedizin Berlin6 papers (2019–2024)Arnd Heuser · Max Delbrück Center6 papers (2018–2024)Ziya Kaya · Heidelberg University6 papers (2018–2021)Clara Bredow · Humboldt-Universität zu Berlin5 papers (2019–2024)Carl Christoph Goetzke · Leibniz Association5 papers (2018–2024)Klaus‐Peter Knobeloch · University of Freiburg4 papers (2018–2024)Francis Impens · VIB-UAntwerp Center for Molecular Neurology4 papers (2019–2024) · 4 papers (2019–2024)Fabien Théry · Purdue University West Lafayette4 papers (2019–2024)Babette Dieringer · Max Delbrück Center4 papers (2019–2024)Nikolaus Berndt · Berlin Institute of Health at Charité - Universitätsmedizin Berlin4 papers (2020–2025)Nicolas Kelm · Humboldt-Universität zu Berlin3 papers (2024–2025)Hannah Louise Neumaier · Humboldt-Universität zu Berlin3 papers (2020–2021)Martin Voß · Goethe University Frankfurt3 papers (2020–2024)Michael Mülleder · Humboldt-Universität zu Berlin3 papers (2024–2025) · 3 papers (2019–2021)Nadine Althof · Federal Institute for Risk Assessment3 papers (2018–2024)